In the UK each year, ovarian cancer is diagnosed in over 6500 women and causes approximately 4400 deaths. Many women present with advanced disease with little prospect of cure. The 5-year survival rate for advanced ovarian cancer between 2005 and 2009 was 43%.
The current standard of care consists of the combination of radical surgery and platinum-based chemotherapy. Although key advances in surgical and chemotherapeutic strategies have led to small improvements in outcome, there still remains a significant risk of recurrence and resistance to therapy and a need to improve current treatment options.
This paper discusses the various available treatment options and areas where further research is needed.